Greg Barrett has more than 35 years of medical device experience. Most recently, Greg was the Chairman, President and CEO of BÂRRX Medical, where he guided the company to a successful sale to a strategic partner. Prior to joining BÂRRX, Greg served as President and CEO of ACMI Corporation, Group Executive Vice President at Boston Scientific Corporation, and he has held positions as Vice President, Global Sales and Marketing at both Orthofix Corporation and Baxter Healthcare. He also spent 13 years at C.R. Bard Corporation, where he finished his tenure as Vice President of Marketing in the Cardiosurgery Division. Greg sits on the Board of BaroSense, Inc. and Cutera, Inc. Greg holds a B.A. in Marketing from the University of Texas, Austin.
Dan Cole joined Oxford Bioscience Partners as a Venture Partner during 2009. He also serves as a General Partner of Spray Venture Partners, which he joined in 1996. Dan brings twenty years of medical device operational experience and has served on the Boards of 26 med-tech companies. Prior to joining Spray, Dan served as Senior Vice President and Group President of Boston Scientific Corporation's vascular business, a $1.2 billion group including SCIMED (cardiology), Medi-tech (radiology), Meadox (vascular surgery), and EP Technologies (electrophysiology). He was also responsible for BSC's rapidly growing international operations. Dan was previously President and Chief Operating Officer of SCIMED Life Systems, a public company with revenues of $260 million in 1994 prior to the company's merger with Boston Scientific in 1995. He previously held a variety of executive and general management positions at Baxter Healthcare Divisions. He currently serves on the board of directors of Direct Flow Medical, TearScience, Conventus, Mitralign, Coherex, Altura, V-wave, Thoratec and Monteris.
He earned a B.S. in Aeronautical Engineering from the University of Kansas, an M.S. in Aeronautical Engineering from the United States Navy Post-Graduate School, and an M.B.A. from the University of California, Los Angeles.
Richard Emmitt is a General Partner of The Vertical Group, a leading venture capital firm specializing in the medical device industry, and was a founder of the firm in 1989. Mr. Emmitt has over 40 years of experience in investment research, investment banking, and investment management. He has been an investor and member of the Board of Directors of several of the medical device industry’s most successful companies including SciMed Life Systems, Xomed Surgical, American Medical Systems, ev3, Inc, and Wright Medical Group. He currently serves on the Board of Directors of Tornier, Tepha Medical, Galil Medical, and Soft Tissue Regeneration. Mr. Emmitt holds a B.A. from Bucknell University and an M.B.A. from the Rutgers School of Business.
Jim Richardson is a retired Vice President of James Richardson & Sons Limited and the current President and Director of Westmead Limited. A graduate of Queens University, Jim has a broad business background and is an investor in several technology and oil and gas companies. He is extremely active in the community being Senior Manitoba Director of Ducks Unlimited, Past Chair of the Nature Conservancy of Canada (Manitoba Region), a trustee of the Richardson Foundation Inc. and the University of Winnipeg Foundation. He was Chair of Sport for the 1999 Pan American Games, Past President of Big Brothers of Canada, a former Regent of the University of Winnipeg and has served on the boards of numerous other community organizations.
Jim is on the Board of Directors of several private Canadian companies including LibreStream Technologies Inc., Monteris Medical Inc., PSI Peripheral Solutions Inc., Telpay Incorporated, NetSecure Innovations Inc., Tundra Oil and Gas Ltd, Lombard Realty Limited, and James Richardson & Sons Limited. In addition, Jim is a member of the Investment Committee of the Lex Capital Partners LP, the Lex Energy Partners LP, and the Lex Energy Partners LP II funds.
Board member biography coming soon.
Mr. Reinstein has more than 25 years of medical device experience. Most recently, he was the President and CEO of Aptus Endosystems Inc. where he recently led the sale of the company to Medtronic. Prior to joining Aptus, James served as Executive Vice-President and Chief Commercial Officer at Cyberonics, a neuromodulation company focused on helping patients with epilepsy, depression and chronic heart failure. Mr Reinstein also spent 17 years at Boston Scientific in various leadership, much of it based outside the in Europe, Asia and Latin America. He graduated with a BA in Marketing from the the University of Georgia. James is currently a General Partner at Palo Alto Medtech Advisors and sits on the board of directors at two publicly traded medical device companies.